To hear about similar clinical trials, please enter your email below
Trial Title:
CAR-T Cells in the Treatment of Malignant Hematological Tumors
NCT ID:
NCT05619861
Condition:
Lymphoma, B-Cell
Leukemia, B-cell
Leukemia, T-Cell
Multiple Myeloma
Conditions: Official terms:
Leukemia
Multiple Myeloma
Lymphoma, B-Cell
Leukemia, B-Cell
Leukemia, T-Cell
Conditions: Keywords:
T cells
Study type:
Interventional
Study phase:
N/A
Overall status:
Unknown status
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
CAR-T
Description:
Patients will receive CAR-T treatment
Arm group label:
CAR-T
Summary:
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent
and refractory hematopoietic and lymphoid tissue tumors
Detailed description:
Main research objective: To evaluate the safety of autologous CAR-T cell injection in the
treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors. Secondary
research objective: To investigate the efficacy and cytodynamic characteristics of
autologous CAR-T cell injection in the treatment of recurrent and refractory
hematopoietic and lymphoid tissue tumors
Criteria for eligibility:
Criteria:
1. With the consent of himself or the legal guardian and the signed informed consent,
he is willing and able to comply with the planned visit, research and treatment,
laboratory examination and other test procedures; Clinical Study of CAR-T Technique
in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
2. Patients with recurrent and refractory hematopoiesis and lymphoid tissue tumors
determined by clinical diagnosis;
3. Age 14-70 (including boundary value), both male and female;
4. Subjects with a physical status of 0~2 in the American Eastern Oncology
Collaboration Group (ECOG);
5. The results of treatment related antigens were positive;
6. The expected life span is more than 3 months from the date of signing the informed
consent;
Gender:
All
Minimum age:
14 Years
Maximum age:
70 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Cangzhou People's Hospital
Address:
City:
Cangzhou
Country:
China
Status:
Recruiting
Contact:
Last name:
Rui Zhang
Phone:
15350769826
Email:
dagang504@163.com
Start date:
April 27, 2020
Completion date:
December 26, 2023
Lead sponsor:
Agency:
Hebei Senlang Biotechnology Inc., Ltd.
Agency class:
Industry
Collaborator:
Agency:
Cangzhou People's Hospital
Agency class:
Other
Source:
Hebei Senlang Biotechnology Inc., Ltd.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05619861
